Compare DexCom, Inc. (DXCM) vs Oatly Group AB - ADR (OTLY) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

OTLY trades at $9.97, up 2.15% today, with a bullish technical signal despite mixed moving averages. Revenue grew to $862M in 2025, but net losses persist at -$153M. The company maintains a strong brand presence, with recent product expansions in Canada and a partnership with Nespresso. Cash burn remains a concern, with negative operating cash flow of -$24M in 2025. Analyst consensus is divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial challenges.

Outlook: OTLY shows potential for growth through market expansion and cost management, but high debt and sustained losses pose significant risks. Investment appeal hinges on achieving profitability and reducing cash burn. Key catalysts include Q2 2026 earnings on July 22, 2026, and execution of strategic initiatives. Risks include liquidity constraints and competitive pressures in the plant-based beverage sector.